Home LiteratureArticle Details
PMID: 17079307 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Journal of virology ·Vol. 81 ·No. 3 ·2007-02-00 ·Pages 1350-9

Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA

Abstract

Biologically functional clade C envelope (Env) glycoproteins from the chronically (donor) and newly (recipient) infected partners of four heterosexual transmission pairs in Zambia were cloned and characterized previously. In each case, the donor viral quasispecies contained Envs that were resistant to autologous neutralization by contemporaneous plasma, while the recipient Envs were sensitive to neutralizing antibodies in this donor plasma sample. The donor Envs also varied in length, glycosylation, and amino acid sequence of the V1V2 hypervariable domain of gp120, while the recipient Envs were much more homogeneous. To assess the contribution of V1V2 to the neutralization phenotype of the donor Envs, V1V2 domains from neutralization-sensitive recipient Envs were replaced with donor V1V2 domains, and the autologous neutralization sensitivities of the chimeric Envs were evaluated using a virus-pseudotyping assay. Long donor V1V2 domains regulated sensitivity to autologous neutralization, although the effect was dependent on the Env background. Short donor V1V2 domains did not confer neutralization resistance. Primary sequence differences in V2 were also found to influence neutralization sensitivity in one set of recipient Envs. The results demonstrate that expansion of the V1V2 domain is one pathway to escape from autologous neutralization in subtype C Envs. However, V1V2-independent mechanisms of resistance also exist, suggesting that escape is multifaceted in chronic subtype C infection.

MeSH Terms
Autoantigens/immunology Cell Line HIV Antibodies/immunology HIV Envelope Protein gp120/chemistry,immunology HIV Infections/immunology HIV-1/immunology Humans Neutralization Tests
Chemicals
Autoantigens HIV Antibodies HIV Envelope Protein gp120
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Rong Rong
Emory Vaccine Center, Emory University, 954 Gatewood Rd., Suite 1024, Atlanta, GA 30329, USA.
Bibollet-Ruche Frederic
Mulenga Joseph
Allen Susan
Blackwell Jerry L
Derdeyn Cynthia A
References (49)
49 references, click to expand
  1. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    J Virol. 2000 Aug;74(15):6769-76 PMID: 10888615
  2. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
    J Virol. 2006 Jul;80(14):7127-35 PMID: 16809318
  3. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.
    J Virol. 2001 Mar;75(5):2041-50 PMID: 11160708
  4. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
    J Virol. 2001 Apr;75(7):3435-43 PMID: 11238869
  5. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
    J Virol. 2001 May;75(9):4208-18 PMID: 11287570
  6. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1067-76 PMID: 11485624
  7. Evolutionary and immunological implications of contemporary HIV-1 variation.
    Br Med Bull. 2001;58:19-42 PMID: 11714622
  8. Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia.
    J Virol. 2002 Jan;76(1):397-405 PMID: 11739704
  9. Diversity considerations in HIV-1 vaccine selection.
    Science. 2002 Jun 28;296(5577):2354-60 PMID: 12089434
  10. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  11. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    J Virol. 2003 Jun;77(12):6965-78 PMID: 12768015
  12. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.
    J Virol. 2003 Jul;77(14):8061-71 PMID: 12829845
  13. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
    J Virol. 2004 Jan;78(1):524-30 PMID: 14671134
  14. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Virology. 2004 Mar 30;321(1):8-22 PMID: 15033560
  15. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Science. 2004 Mar 26;303(5666):2019-22 PMID: 15044802
  16. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
    J Virol. 2004 May;78(10):5205-15 PMID: 15113902
  17. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52 PMID: 1717992
  18. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    J Virol. 1992 Feb;66(2):848-56 PMID: 1370558
  19. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
    J Virol. 1993 Aug;67(8):4932-44 PMID: 7687306
  20. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    J Virol. 1994 Jan;68(1):400-10 PMID: 7504740
  21. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.
    J Virol. 1994 Apr;68(4):2253-9 PMID: 8139010
  22. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
    J Clin Invest. 1994 Jun;93(6):2505-13 PMID: 7515393
  23. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.
    J Virol. 1994 Jul;68(7):4636-42 PMID: 7515975
  24. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8312-20 PMID: 7525987
  25. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Arch Virol. 1994;139(3-4):253-61 PMID: 7832633
  26. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.
    Virology. 1995 Feb 1;206(2):878-84 PMID: 7856100
  27. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
    J Virol. 1995 Apr;69(4):2271-8 PMID: 7533854
  28. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  29. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells.
    J Virol. 1996 Feb;70(2):1310-6 PMID: 8551601
  30. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
    J Virol. 1997 Oct;71(10):7719-27 PMID: 9311856
  31. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
    AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1291-9 PMID: 9339846
  32. Rapid HIV testing and counseling for voluntary testing centers in Africa.
    AIDS. 1997 Sep;11 Suppl 1:S103-10 PMID: 9376093
  33. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  34. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
    J Virol. 1998 Oct;72(10):7840-5 PMID: 9733820
  35. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.
    J Virol. 1998 Oct;72(10):8437-45 PMID: 9733899
  36. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
    J Virol. 1999 Jul;73(7):5294-300 PMID: 10364275
  37. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    J Virol. 2004 Dec;78(23):13232-52 PMID: 15542675
  38. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
    J Virol. 2005 Jan;79(2):780-90 PMID: 15613306
  39. Structure of an unliganded simian immunodeficiency virus gp120 core.
    Nature. 2005 Feb 24;433(7028):834-41 PMID: 15729334
  40. Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages.
    J Virol. 2005 Apr;79(8):4828-37 PMID: 15795268
  41. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.
    J Virol. 2005 Apr;79(8):5232-7 PMID: 15795308
  42. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.
    J Virol. 2005 May;79(10):6528-31 PMID: 15858037
  43. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    J Virol. 2005 Jun;79(11):6909-17 PMID: 15890930
  44. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
    J Virol. 2005 Jul;79(14):9069-80 PMID: 15994801
  45. Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.
    Retrovirology. 2005;2:67 PMID: 16274482
  46. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
    J Virol. 2006 Jan;80(2):750-8 PMID: 16378977
  47. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.
    J Virol. 2006 Jan;80(2):835-44 PMID: 16378985
  48. Global epidemiology of HIV.
    J Med Virol. 2006;78 Suppl 1:S7-S12 PMID: 16622870
  49. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.
    J Virol. 2006 Jun;80(11):5211-8 PMID: 16699001
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2007-02-00
Epub
2006-00-01
Pages
1350-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1797511
Subset
IM
Grants
NCRR NIH HHS · RR-00165 · United States
NIAID NIH HHS · R01 AI051231 · United States
NIAID NIH HHS · R01 AI058706 · United States
NCRR NIH HHS · P51 RR000165 · United States
NIAID NIH HHS · R01-AI-51231 · United States
NIAID NIH HHS · R01-AI-58706 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com